BLINCYTO biosimilars — when can they launch?
BLINCYTO (blinatumomab) · BLA125557 · AMGEN
Where BLINCYTO sits in the biosimilar timeline
BPCIA 12-year reference product exclusivity for BLINCYTO expires in 2026 (1 year from today). Biosimilar developers are typically preparing 351(k) applications 36-48 months ahead of this date. Expect first biosimilar filings to surface in this window.
Under the US Biologics Price Competition and Innovation Act (BPCIA), a reference biologic is protected from biosimilar competition for 12 years from FDA approval (with 4 years of data exclusivity preventing 351(k) submissions). Biosimilars enter via the abbreviated 351(k) pathway, which requires comparability — not exact identity — to the reference product.
Key dates for BLINCYTO
| Event | Date | Status |
|---|---|---|
| FDA approval (BLA filed by AMGEN) | 2014-12-03 | Past |
| 4-year data exclusivity ends (first biosimilar 351(k) submission permitted) | 2018-12-03 | Past |
| 12-year reference product exclusivity ends (first biosimilar can be marketed) | 2026-12-03 | Future |
Note: composition-of-matter and method-of-use patent expiries (separate from BPCIA exclusivity) may set the actual launch window. See BLINCYTO on Drug Landscape for the full patent picture.
Other AMGEN biologics
Sources
- FDA Purple Book — biologic license applications + BPCIA exclusivity
- BLINCYTO drug profile — full patent estate, indications, clinical trials
- AMGEN patent portfolio
Not legal advice. BPCIA exclusivity may interact with composition-of-matter patents and patent term extensions — see the full drug profile for the consolidated picture.
Track BLINCYTO biosimilar entry
Daily alerts when BPCIA exclusivity, ref-product patents, or biosimilar applications change. Free 3 watches, Pro 50.